Daewoong and Samyangsa on strategic tie-up.

Published: 2000-02-01 11:20:00

Updated: 2000-02-01 11:20:00

Daewoong and Samyangsa made a strategic business tie-up on Jan. 21 for the production and the marketing of the patch type of drugs, aiming at a synergic effect by both parties who may intensify and exchange their powerful strength each other in production and marketing of a new type of drugs in t...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK